A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

医学 安慰剂 肾病 双盲 内科学 随机对照试验 临床试验 内分泌学 糖尿病 替代医学 病理
作者
Richard A. Lafayette,Sean Barbour,Rubeen Israni,Xuelian Wei,Necmi Eren,Jürgen Floege,Vivekanand Jha,Sung Gyun Kim,Bart Maes,Richard Phoon,Harmeet Singh,Vladimı́r Tesař,Celia J. F. Lin,Jonathan Barratt
出处
期刊:Kidney International [Elsevier BV]
卷期号:105 (6): 1306-1315 被引量:37
标识
DOI:10.1016/j.kint.2024.03.012
摘要

Atacicept is a first-in-class, dual anti-B-cell Activation Factor–A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in patients with IgAN, this randomized, double-blind, placebo-controlled phase 2b clinical trial ORIGIN enrolled 116 individuals with biopsy-proven IgA nephropathy. Participants were randomized to atacicept 150, 75, or 25 mg versus placebo once weekly for up to 36 weeks. Primary and key secondary endpoints were changes in urine protein creatinine ratio based on 24-hour urine collection at weeks 24 and 36, respectively, in the combined atacicept 150 mg and 75 mg group versus placebo. The primary endpoint was met at week 24 as the mean urine protein creatinine ratio was reduced from baseline by 31% in the combined atacicept group versus 8% with placebo, resulting in a significant 25% reduction with atacicept versus placebo. At week 36, the key secondary endpoint was met as the mean urine protein creatinine ratio reduced from baseline by 34% in the combined atacicept group versus a 2% increase with placebo, resulting in a significant 35% reduction with atacicept versus placebo. The reduction in proteinuria was accompanied by stabilization in endpoint eGFR with atacicept compared to a decline with placebo at week 36, resulting in significant between-group geometric mean difference of 11%, approximating an absolute difference of 5.7 mL/min/1.73m 2. Endpoint galactose deficient IgA1 levels significantly decreased from baseline by 60% versus placebo. The safety profile of atacicept was like placebo. Thus, our results provide evidence to support a pivotal, phase 3 study of atacicept in IgA nephropathy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
善良冷松发布了新的文献求助10
刚刚
2秒前
在水一方应助一定行采纳,获得10
3秒前
3秒前
3秒前
NexusExplorer应助快乐一江采纳,获得10
4秒前
4秒前
科研通AI5应助Lcccccc采纳,获得10
4秒前
在水一方应助杰2580采纳,获得10
7秒前
幸福大白发布了新的文献求助30
7秒前
Jasmine发布了新的文献求助10
7秒前
8秒前
善良冷松完成签到,获得积分10
8秒前
8秒前
善学以致用应助fengliurencai采纳,获得10
9秒前
个别完成签到,获得积分10
10秒前
10秒前
10秒前
11秒前
sihanzhiyu完成签到,获得积分20
12秒前
12秒前
wdy111应助ASZXDW采纳,获得20
14秒前
14秒前
wsj发布了新的文献求助10
14秒前
旧梦发布了新的文献求助10
14秒前
东晓发布了新的文献求助10
15秒前
科研通AI5应助科研通管家采纳,获得10
15秒前
bkagyin应助科研通管家采纳,获得10
15秒前
共享精神应助科研通管家采纳,获得10
15秒前
852应助科研通管家采纳,获得10
15秒前
NexusExplorer应助科研通管家采纳,获得10
15秒前
酷波er应助科研通管家采纳,获得10
16秒前
从容的鲜花完成签到,获得积分10
16秒前
酷波er应助科研通管家采纳,获得10
16秒前
CAOHOU应助科研通管家采纳,获得10
16秒前
研友_VZG7GZ应助科研通管家采纳,获得10
16秒前
SYLH应助科研通管家采纳,获得10
16秒前
SYLH应助科研通管家采纳,获得10
16秒前
田様应助科研通管家采纳,获得10
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989390
求助须知:如何正确求助?哪些是违规求助? 3531487
关于积分的说明 11254109
捐赠科研通 3270153
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809174